Ann: FDA Approves Sofdra, page-505

I don't see it under pressure at all myself.

The last week has seen steady trade keeping it at 7 to 14% above the CR price and trading volumes less than a 5th than when Sofdra got FDA approval and the CR was announced. What we see here is entirely normal following a cap raise at a price less than where it sits presently. Now if the volumes we up in the 30/40/50m then possibly there'd be some pressure, but what we see presently is just BAU waiting for the next announcement, following a 30c cap raise. But each to their own opinion.